Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diabetes Therapy
Cardiovascular effects of rosiglitazone reviewed
September 27th, 2004
Researchers review the cardiovascular effects of rosiglitazone in a recent issue of Presse Medicale. According to published research from France, "Since their launch on the French market in 2002, thiazolidinediones ('glitazones') prescribing conditions and therapeutic indications have progressively widened, although remaining strictly defined by the marketing license. Clinical efficacy on glycemic control (HbA1c and glycemia), as well as beneficial metabolic effects (on lipids, insulin resistance, and beta-cellular function) are now well established. Their side effects, generally minor or mild, are also well known." "The problem of...
Source: Diabetes Week (2004-09-27)
|
